{"product_id":"pt-141-bremelanotide-20mg","title":"PT-141 (Bremelanotide) 20mg","description":"\u003cp\u003ePT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist studied for its role in sexual arousal and central libido signaling. Unlike PDE-5 inhibitors, it acts directly on the central nervous system via melanocortin pathways. In clinical research, it has been observed to increase sexual desire scores in both male and female populations. Administered subcutaneously, PT-141 supports hypothalamic activation and neurotransmitter modulation in controlled research settings.\u003c\/p\u003e\n\u003cdiv class=\"elementor-element elementor-element-70108bd elementor-widget elementor-widget-heading\" data-id=\"70108bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003ePen Dosage Chart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-a2c1f5a color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"a2c1f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\" style=\"width: 100%;\"\u003e\n\u003ccolgroup\u003e \u003ccol width=\"50%\" style=\"width: 21.033868%;\"\u003e \u003ccol width=\"50%\" style=\"width: 78.787879%;\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003ePT-141 (Bremelanotide) 10 mg QuickPen Pro\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003e3.0 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emg\/mL\u003c\/td\u003e\n\u003ctd\u003e3.33 mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClick-to-Dose\u003c\/td\u003e\n\u003ctd\u003e1 click = 0.033 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample(s)\u003c\/td\u003e\n\u003ctd\u003e30 clicks(10 of Pen Scale) = 1 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"425\" data-end=\"839\"\u003e \u003c\/p\u003e\n\u003cp\u003ePT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from alpha-MSH analog research. It belongs to the class of neuroactive peptide hormones targeting melanocortin receptors, particularly MC4R and MC3R. PT-141 is primarily studied in domains such as sexual function research, central arousal signaling, and hypothalamic neurobiology. Unlike peripheral vasodilators, its mechanism is centrally mediated within the brain.\u003c\/p\u003e\n\u003cp\u003eOur formulation is provided in a stabilized pre-mixed injection pen for SubQ administration. Subcutaneous delivery supports reliable systemic exposure and consistent CNS signaling activation in research protocols. Each unit is freshly prepared to maintain peptide integrity and standardized dosing. This format eliminates multi-step vial preparation and simplifies laboratory handling. The product is formulated strictly for research use only.\u003c\/p\u003e\n\u003cp\u003eIn clinical and preclinical studies, PT-141 has been shown to activate melanocortin receptors in the hypothalamus → ↑ dopaminergic signaling and ↑ sexual motivation pathways. Research indicates modulation of limbic system activity associated with arousal and desire. Unlike PDE-5 inhibitors, PT-141 does not primarily act on nitric oxide-mediated vasodilation.\u003c\/p\u003e\n\u003cdiv class=\"elementor-element elementor-element-461454e elementor-widget elementor-widget-heading\" data-id=\"461454e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eMechanism of Action\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-89ab6a4 color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"89ab6a4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003cp\u003ePT-141 activates melanocortin receptors in the central nervous system, particularly MC4R receptors within the hypothalamus. Activation of these receptors influences dopamine release → ↑ sexual motivation and arousal signaling. Unlike PDE-5 inhibitors, PT-141 does not depend primarily on peripheral blood flow modulation. Instead, it acts upstream at the level of neural desire circuits. This central mechanism differentiates it from vasodilatory erectile function agents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-bf2e85c elementor-widget elementor-widget-menu-anchor\" data-id=\"bf2e85c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"menu-anchor.default\"\u003e\n\u003cdiv id=\"3\" class=\"elementor-menu-anchor\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-3839bb6 elementor-widget elementor-widget-heading\" data-id=\"3839bb6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eBenefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-a88a59d color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"a88a59d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003cul\u003e\n\u003cli\u003eCentral Activation Of Sexual Motivation Circuits:\u003cbr\u003ePT-141 has been studied for its ability to activate melanocortin receptors within hypothalamic nuclei associated with sexual motivation and arousal behavior. Unlike peripheral vasodilators, this peptide acts directly on central neural circuits governing desire. Clinical trials demonstrate ↑ sexual desire scores and ↑ frequency of satisfying sexual events in controlled populations. Neuroimaging and behavioral research suggest involvement of limbic structures linked to reward anticipation. Activation of melanocortin signaling → ↑ dopaminergic transmission in mesolimbic pathways. This central mechanism positions PT-141 as a neuroendocrine modulator rather than a vascular agent. Evidence type: Human RCT ✔ | Observational ✔.\u003c\/li\u003e\n\u003cli\u003eSelective MC4R And MC3R Receptor Agonism:\u003cbr\u003ePT-141 selectively binds melanocortin-4 receptors (MC4R) and melanocortin-3 receptors (MC3R) expressed in hypothalamic and limbic regions. MC4R activation triggers adenylate cyclase → ↑ cAMP production → modulation of downstream dopamine signaling. Preclinical models confirm behavioral changes associated with receptor stimulation. This receptor-level specificity differentiates PT-141 from hormonal therapies that broadly alter endocrine balance. Research also indicates interaction with pro-opiomelanocortin (POMC) neurons → modulation of motivational circuitry. These receptor interactions underpin its central arousal profile.\u003c\/li\u003e\n\u003cli\u003eDopaminergic Reward Circuit Enhancement:\u003cbr\u003eMelanocortin receptor activation influences mesolimbic dopamine pathways projecting from the ventral tegmental area to the nucleus accumbens. PT-141 administration has been associated with ↑ dopaminergic activity in reward-processing regions in animal models. Dopamine plays a central role in sexual motivation and anticipatory behavior. This pathway differs fundamentally from nitric oxide-mediated smooth muscle relaxation. By acting upstream in motivational circuitry, PT-141 influences desire rather than only physiological response.\u003c\/li\u003e\n\u003cli\u003eIndependence From Nitric Oxide Vasodilation:\u003cbr\u003eUnlike PDE-5 inhibitors such as sildenafil, PT-141 does not primarily increase nitric oxide production or inhibit phosphodiesterase enzymes. Its mechanism does not rely on peripheral vasodilation of penile smooth muscle. Instead, central melanocortin activation → ↑ neural arousal signaling, which may secondarily influence physiological response. This distinction allows evaluation in populations where vascular function is not the primary limiting factor. Research highlights mechanistic divergence from traditional erectile function compounds.\u003c\/li\u003e\n\u003cli\u003eFemale Sexual Desire Research And Regulatory Validation:\u003cbr\u003eClinical studies in female populations with hypoactive sexual desire research diagnoses demonstrate measurable improvements in desire-related endpoints. Phase trials report statistically significant ↑ sexual desire scores compared to placebo. These effects are centrally mediated and not dependent on hormonal replacement mechanisms. Regulatory approval in certain jurisdictions reflects controlled human data supporting this pathway. Evidence type: Human RCT ✔.\u003c\/li\u003e\n\u003cli\u003eMale Arousal Signaling And Behavioral Response Models:\u003cbr\u003eIn male research populations, PT-141 has been associated with enhanced erectile response secondary to central activation. Preclinical studies show ↑ mounting behavior and ↑ copulatory motivation in animal models. These behavioral changes occur independently of direct smooth muscle relaxation mechanisms. Central dopaminergic activation is considered the primary driver of these effects. Evidence type: Human studies ✔ | Animal ▣.\u003c\/li\u003e\n\u003cli\u003ePOMC Neuron Activation And Melanocortin System Engagement:\u003cbr\u003ePT-141 activates pro-opiomelanocortin (POMC) neurons within the arcuate nucleus of the hypothalamus. POMC activation → release of melanocortin peptides influencing motivational and reward circuits. This engagement extends beyond sexual signaling and interacts with broader appetite and reward biology pathways. The melanocortin system plays a key role in behavioral drive regulation. This systems-level activation distinguishes PT-141 from peripheral-only agents.\u003c\/li\u003e\n\u003cli\u003eNeuroendocrine Integration Without Direct Testosterone Modulation:\u003cbr\u003ePT-141 does not directly increase testosterone production or replace androgen pathways. Its effects occur independently of gonadal hormone elevation. This allows central arousal signaling without broad endocrine disruption. Clinical endocrine panels demonstrate minimal direct hormonal alteration under therapeutic dosing in research settings. The mechanism remains neurocentric rather than systemic hormonal.\u003c\/li\u003e\n\u003cli\u003ePredictable Subcutaneous Pharmacokinetics:\u003cbr\u003eProvided in a stabilized pre-mixed injection pen for SubQ administration, PT-141 demonstrates reliable systemic absorption in clinical research. Subcutaneous delivery supports controlled plasma concentration curves and predictable onset windows in human trials. This route allows rapid engagement of central melanocortin pathways. Each unit is prepared fresh and intended strictly for research use only.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"Default Title","offer_id":57226888937849,"sku":null,"price":89.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/pt-141-bremelanotide-20mg-6845880.png?v=1778161510","url":"https:\/\/www.quickpen.pro\/products\/pt-141-bremelanotide-20mg","provider":"Quickpen Pro Peptides","version":"1.0","type":"link"}